Is Seleniso reimbursable through health insurance?

Since its approval, Selinexor, as the country's first new selective nuclear export inhibitor anti-tumor drug, has been gradually included in the clinical treatment of refractory diseases such as multiple myeloma and large B-cell lymphoma. In recent years, with the dynamic adjustment of medical insurance policies, Selinexor's original drug has also successfully entered the national medical insurance catalog and became a Class B medical insurance drug, which has greatly reduced the financial burden on patients. However, it needs to be emphasized that medical insurance reimbursement is not open to all patients, but only certain indications can be reimbursed.

According to the latest medical insurance directory, the medical insurance indications for selinesol include two categories: the first category is adult patients with relapsed or refractory multiple myeloma who have received previous treatment and are resistant to at least one proteasome inhibitor, one immunomodulator and one anti-CD38 monoclonal antibody; the second category is adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two systemic treatments in the past. These restrictions ensure the accurate use of medical insurance resources, while also providing practical help to patients with real treatment needs.

Currently, the common specifications of selinexol on the market are20 mg, usually 12 tablets/box or 16 tablets/box, and the price per box is about 20,000 yuan. After medical insurance reimbursement, the actual patient out-of-pocket amount will be significantly reduced, but the reimbursement ratio may be slightly different in different places. You need to refer to the relevant policies of the local medical insurance bureau. Some regions even provide secondary reimbursement or "serious disease" policy support to further reduce the burden on patients.

In short, the medical insurance reimbursement of Seleniso has formed a clear path in China, but it must be judged by clinicians based on the patient's specific condition and applied according to the process. It is recommended that patients consult the pharmaceutical department or medical insurance office of a formal medical institution before taking medication to ensure that the information is complete and the medication is compliant, so as to obtain maximum reimbursement support, thereby improving treatment accessibility and sustainability.

Reference materials:https://www.selincro.com/